MHRA approves Seagen’s oral HER2 drug TukysaThe UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after Share XMHRA approves Seagen’s oral HER2 drug Tukysahttps://pharmaphorum.com/news/mhra-approves-seagens-oral-her2-drug-tukysa/
Merck & Co signs multi-billion cancer drug development deal with Seattle GeneticsMerck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion Share XMerck & Co signs multi-billion cancer drug development deal with Seattle Geneticshttps://pharmaphorum.com/news/merck-co-signs/
Seattle Genetics snags early approval for advanced breast cancer drugThe FDA has approved Seattle Genetics’ breast cancer drug Tukysa (tucatinib) four months early, including in certain patients Share XSeattle Genetics snags early approval for advanced breast cancer drughttps://pharmaphorum.com/news/fda-approves-seattle-genetics-advanced-breast-cancer-drug/
FDA sets August action date for Seattle’s oral HER2 drug tucatinibSeattle Genetics is a few months away from having its third drug product on the market, after the Share XFDA sets August action date for Seattle’s oral HER2 drug tucatinibhttps://pharmaphorum.com/news/fda-sets-august-action-date-for-seattles-oral-her2-drug-tucatinib/
Seattle Genetics says data backs Padcev combo for first-line bladder cancerSeattle Genetics and Astellas’ new drug for relapsed bladder cancer – Padcev – could move up the treatment Share XSeattle Genetics says data backs Padcev combo for first-line bladder cancerhttps://pharmaphorum.com/news/seattle-genetics-says-data-backs-padcev-combo-for-first-line-bladder-cancer/
FDA backs Astellas/Seattle Genetics bladder cancer drugThe FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the Share XFDA backs Astellas/Seattle Genetics bladder cancer drughttps://pharmaphorum.com/news/fda-backs-astellas-seattle-genetics-bladder-cancer-drug/
AZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseaseAstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi Share XAZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseasehttps://pharmaphorum.com/news/az-daiichi-sankyos-breast-cancer-drug-delays-progression-in-advanced-disease/
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalatesBig-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and Share XDaiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalateshttps://pharmaphorum.com/news/daiichi-sankyo-takes-seattle-genetics-to-court-as-battle-over-breast-cancer-drug-escalates/
Seattle Genetics plans to file breast cancer drug tucatinibSeattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in Share XSeattle Genetics plans to file breast cancer drug tucatinibhttps://pharmaphorum.com/news/seattle-genetics-plans-to-file-breast-cancer-drug/
